Evidence map›Paper›PMID 28429310›Full record

ArticleAnnals of intensive care2017

The protective association of endogenous immunoglobulins against sepsis mortality is restricted to patients with moderate organ failure.

Ignacio Martin-Loeches, Arturo Muriel-Bombín, Ricard Ferrer, Antonio Artigas, Jordi Sole-Violan, Leonardo Lorente, David Andaluz-Ojeda, Adriele Prina-Mello, Ruben Herrán-Monge, Borja Suberviola and 10 more

Open access · goldAbstract read
In one paragraph

Article in Annals of intensive care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Focus on infection.Intensive care medicine · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Immunoglobulins and sepsis.Intensive care medicine · 2018
    Review
  19. Review
  20. Current aspects in sepsis approach. Turning things around.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 2 countries.

Ignacio Martin-LoechesMultidisciplinary Intensive Care Research Organization (MICRO), St. James's University Hospitals Dublin, James's St, Ushers, Dublin 8, Ireland.
Arturo Muriel-BombínIntensive Care Department, Hospital Universitario Río Hortega de Valladolid, Calle Dulzaina, 2, 47012, Valladolid, Spain.
Ricard FerrerIntensive Care Department, Vall d'Hebron University Hospital, Shock Organ Dysfunction and Resuscitation Research Group, Vall d' Hebron Research Institute, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Antonio ArtigasABISS-Edusepsis (AntiBiotic Intervention in Severe Sepsis), Intensive Care Department, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Jordi Sole-ViolanABISS-Edusepsis (AntiBiotic Intervention in Severe Sepsis), Intensive Care Department, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Leonardo LorenteABISS-Edusepsis (AntiBiotic Intervention in Severe Sepsis), Intensive Care Department, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
David Andaluz-OjedaCritical Care Medicine Service, Hospital Clínico Universitario de Valladolid, Av. Ramón y Cajal, 3, 47003, Valladolid, Spain.
Adriele Prina-MelloLaboratory for Biological Characterisation of Advanced Materials, Trinity Translational Medicine Institute (TTMI), James's St, Dublin 8, Ireland.
Ruben Herrán-MongeIntensive Care Department, Hospital Universitario Río Hortega de Valladolid, Calle Dulzaina, 2, 47012, Valladolid, Spain.
Borja SuberviolaABISS-Edusepsis (AntiBiotic Intervention in Severe Sepsis), Intensive Care Department, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Ana Rodriguez-FernandezMicrobiology Service, Hospital Marques de Valdecilla, Av. Valdecilla, 25, 39008, Santander, Spain.
Pedro MerinoIntensive Care Department, Hospital Universitario Río Hortega de Valladolid, Calle Dulzaina, 2, 47012, Valladolid, Spain.
Ana M LozaABISS-Edusepsis (AntiBiotic Intervention in Severe Sepsis), Intensive Care Department, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Pablo Garcia-OlivaresABISS-Edusepsis (AntiBiotic Intervention in Severe Sepsis), Intensive Care Department, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Eduardo AntonABISS-Edusepsis (AntiBiotic Intervention in Severe Sepsis), Intensive Care Department, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
Eduardo TamayoAnesthesiology Service, Hospital Clínico Universitario de Valladolid, Av. Ramón y Cajal, 47003, Valladolid, Spain.
Wysali TrapielloBIO∙SEPSIS (Laboratory of Biomedical Research in Sepsis), Hospital Clínico Universitario, SACYL, Av. Ramón y Cajal 3, 47003, Valladolid, Spain.
Jesús BlancoIntensive Care Department, Hospital Universitario Río Hortega de Valladolid, Calle Dulzaina, 2, 47012, Valladolid, Spain.
Jesús F Bermejo-MartinBIO∙SEPSIS (Laboratory of Biomedical Research in Sepsis), Hospital Clínico Universitario, SACYL, Av. Ramón y Cajal 3, 47003, Valladolid, Spain. jfbermejo@saludcastillayleon.es.
GRECIA group
Hospital Clínico Universitario de Valladolid · ESInstituto de Salud Carlos III · ESVall d'Hebron Hospital Universitari · ESMarqués de Valdecilla University Hospital · ESSt. James's Hospital · IEVall d'Hebron Institut de Recerca · ESFundación Hospital Manacor · ESHospital General Universitario Gregorio Marañón · ESHospital Universitario de Canarias · ESHospital Universitario de Gran Canaria Doctor Negrín · ESHospital Universitario Río Hortega · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPre-evaluation of endogenous immunoglobulin levels is a potential strategy to improve the results of intravenous immunoglobulins in sepsis, but more work has to be done to identify those patients who could benefit the most from this treatment. The objective of this study was to evaluate the impact of endogenous immunoglobulins on the mortality risk in sepsis depending on disease severity.

methodsThis was a retrospective observational study including 278 patients admitted to the ICU with sepsis fulfilling the SEPSIS-3 criteria, coming from the Spanish GRECIA and ABISS-EDUSEPSIS cohorts. Patients were distributed into two groups depending on their Sequential Organ Failure Assessment score at ICU admission (SOFA < 8, n = 122 and SOFA ≥ 8, n = 156), and the association between immunoglobulin levels at ICU admission with mortality was studied in each group by Kaplan-Meier and multivariate logistic regression analysis.

resultsICU/hospital mortality in the SOFA < 8 group was 14.8/23.0%, compared to 30.1/35.3% in the SOFA ≥ 8 group. In the group with SOFA < 8, the simultaneous presence of total IgG < 407 mg/dl, IgM < 43 mg/dl and IgA < 219 mg/dl was associated with a reduction in the survival mean time of 6.6 days in the first 28 days and was a robust predictor of mortality risk either during the acute or during the post-acute phase of the disease (OR for ICU mortality: 13.79; OR for hospital mortality: 7.98). This predictive ability remained in the absence of prior immunosuppression (OR for ICU mortality: 17.53; OR for hospital mortality: 5.63). Total IgG < 407 mg/dl or IgG1 < 332 mg/dl was also an independent predictor of ICU mortality in this group. In contrast, in the SOFA ≥ 8 group, we found no immunoglobulin thresholds associated with neither ICU nor hospital mortality.

conclusionsEndogenous immunoglobulin levels may have a different impact on the mortality risk of sepsis patients based on their severity. In patients with moderate organ failure, the simultaneous presence of low levels of IgG, IgA and IgM was a consistent predictor of both acute and post-acute mortalities.

Indexed as

ImmunoglobulinsSepsisSeveritySurvival

Identifiers

PMID28429310
PMCPMC5399013
OpenAlexW2606187889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.